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Kaposi’s sarcoma-associated herpesvirus (KSHV) is necessary for KS, a highly vascularized tumor predominated by endothelial-derived
spindle cells that express markers of lymphatic endothelium. Following KSHV infection of TIME cells, an immortalized human dermal
microvascular endothelial cell (DMVEC) line, expression of many genes specific to lymphatic endothelium, including VEGFR3, podoplanin,
LYVE-1, and Prox-1, is significantly increased. Increases in VEGFR3 and podoplanin protein are also demonstrated following latent
infection. Examination of cytokine secretion showed that KSHV infection significantly induces hIL-6 while strongly inhibiting secretion of
IL-8, a gene product that is decreased by differentiation of blood to lymphatic endothelial cells. These studies support the hypotheses that
latent KSHV infection of blood endothelial cells drives their differentiation to lymphatic endothelial cells.
D 2004 Elsevier Inc. All rights reserved.
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Kaposi’s sarcoma (KS), the most frequent malignancy in
AIDS patients, is currently the most commonly reported
tumor in parts of Africa (Wabinga et al., 1993). KS tumors are
highly vascularized and exhibit extensive neoangiogenesis.
KS tumors also contain increased levels of several pro-
inflammatory cytokines, including hIL-6 (Oxholm et al.,
1989). The most prominent cell in the KS tumor is the spindle
cell, a cell of endothelial origins, though there are other cell
types present in the tumor including infiltrating lymphocytes.
KS spindle cells express elevated levels of vascular endo-
thelial growth factor receptor 3 (VEGFR3) and podoplanin,
two specific markers of the lymphatic endothelium (Jussila et
al., 1998; Skobe et al., 1999), which led to the hypothesis that
KS spindle cells are lymphatic in origin (Jussila et al., 1998;
Skobe et al., 1999; Weninger et al., 1999). The lymphatic0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: Lagunoff@u.washington.edu (M. Lagunoff).endothelium controls the fluid and lymphocyte uptake into
lymph nodes and is architecturally distinct from the blood
vascular endothelium. Lymphangiogenesis is a separate
process from blood or hemangiogenesis, utilizing different
VEGF family members, primarily VEGF-C and D and their
receptor VEGFR3 (Makinen et al., 2001).
Kaposi’s sarcoma-associated herpesvirus (KSHV also
known as human herpesvirus 8 or HHV-8) is present in
spindle cells of all KS tumors and is necessary for KS
progression (Aluigi et al., 1996). KSHV is also associated
with two B-cell lymphoproliferative diseases, primary
effusion lymphoma (PEL) (Cesarman et al., 1995) and
AIDS-associated plasmablastic multicentric Castleman’s
disease (MCD) (Soulier et al., 1995). KSHV is a gamma
herpesvirus, further subclassified as a rhadinovirus. At least
80 genes are encoded on its 165-kilobase genome (Neipel et
al., 1997; Russo et al., 1996). Like all herpesviruses, KSHV
has both a lytic and a latent phase. During latency, a small
subset of the coding capacity of KSHV is expressed. In KS
tumors and primary effusion lymphomas, KSHV is found
predominantly in the latent state, although there is always a
low background of lytic replication (Staskus et al., 1997).2004) 7–18
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cells (DMVECs) immortalized with h-tert, the active subunit
of telomerase, and are efficiently infected with KSHV. By
24 h postinfection, nearly all of the TIME cells support
latent infection while around 1–3% undergo lytic replica-
tion, similar to the percentages in KS tumors and PELs
(Lagunoff et al., 2002). The studies presented here
demonstrate that KSHV infection of TIME cells induces
many changes that are consistent with differentiation from
blood to lymphatic endothelial cells (BEC to LEC). This
supports the hypothesis that KSHV infection of BECs in
vivo causes them to differentiate into LECs as they
transform into spindle cells.Fig. 1. KSHV infection of TIME cells induces specific markers of
lymphatic endothelial cells. (A) Depicted is the fold change of LEC-
specific transcripts in KSHV-infected TIME cells compared to UV-
irradiated virus-treated cells at 48 h postinfection as determined by real-
time RT-PCR (N = 3–5). All values were normalized to GAPDH expression
and error bars represent the standard error of the mean. (B) Shown is a
representational gel of Prox-1 and GAPDH mRNA amplification by semi-
quantitative RT-PCR from mock- and KSHV-infected TIME cells. (C)
Western blot analysis of VEGFR3 podoplanin in mock- and KSHV-infected
TIME cells. Cox1 is included as a loading control.Results
Markers of lymphatic endothelial cells are induced by
KSHV infection
To examine major markers of lymphatic endothelial
cells, we used quantitative real-time RT-PCR to examine
expression of VEGFR3, podoplanin, and LYVE-1 in TIME
cells infected with KSHV or with KSHV that was UV
irradiated. UV-irradiated virus can bind and enter cells but
there is no viral gene expression. Infection rates were
determined by seeding a subset of infected cells onto slides
at the time of harvest and staining with antibodies to a latent
marker (LANA) and a lytic marker (ORF 59). Only
experiments where greater than 90% of the cells expressed
latent markers and less than 5% of the cells expressed lytic
markers were analyzed. No staining was seen in uninfected
cells or cells infected with UV-irradiated virus. Expression
of VEGFR3, podoplanin, and LYVE-1 is increased approx-
imately 10-, 13-, and 7-fold, respectively, in KSHV-infected
cells (Fig. 1A). Prox-1 is required for the developmental
expression of VEGFR3 and podoplanin as BECs differ-
entiate into LECs in vivo (Wigle and Oliver, 1999), thus
making the Prox-1 pathway a likely cellular target of KSHV.
We could not amplify an RT-PCR product using primers
specific for Prox-1 when using mRNA from uninfected or
UV-irradiated KSHV-infected TIME cells, but we could
amplify product from mRNA isolated from KSHV-infected
TIME cells (Fig. 1B). The 2.2-kb product was subcloned,
sequenced, and found to be full-length Prox-1 mRNA (data
not shown). This indicates that uninfected TIME cells
express little, if any, Prox-1, and the gene is upregulated by
KSHV infection. Interestingly, we could easily amplify
Prox-1 using mRNA from uninfected primary DMVECs
(data not shown). It was previously shown that commer-
cially available DMVECs are a mixture of blood and
lymphatic endothelial cells (Makinen et al., 2001). Thus, it
is likely that the contaminating LECs express the Prox-1
detected. The complete lack of detectable Prox-1 in TIME
cells provides evidence that TIME cells are purely BEC in
origin.We also analyzed the protein levels of lymphatic
endothelial-specific markers. Cell lysates from uninfected
and KSHV-infected TIME cells were analyzed by Western
blot using antibodies to VEGFR3 and podoplanin. Both
were initially below the threshold of detection by Western
blot, but easily detected following infection (Fig. 1C). We
also examined expression of podoplanin in cells using
immunofluorescence. There was only light background
staining with an anti-podoplanin antibody in uninfected
cells while there is strong cytoplasmic membrane staining in
KSHV-infected TIME cells (Fig. 2). Importantly, around
90% of these cells express LANA and less than 1% express
markers of lytic replication, indicating expression of
lymphatic markers is due to latent gene expression. Also
of note, the high level of podoplanin staining is only seen in
Fig. 2. Podoplanin expression is increased in latently infected TIME cells. TIME cells that are N90% latently infected and b1% lytically infected with KSHV
and matched mock-infected cells were fixed 72 h after infection and co-stained with anti-podoplanin antibody (green), anti-LANA (red), and DAPI (blue) to
stain the nuclei. Only those infected cells that express LANA exhibit cytoplasmic membrane staining for podoplanin.
Rapid Communication 9LANA-positive cells in the infected cell panel (Fig. 2).
Taken together, these data indicate that latent KSHV
infection of BECs leads to differentiation to LECs.
Global changes in mRNA expression after KSHV infection
To identify global changes in gene expression caused
by KSHV infection of endothelial cells, we used cDNA
microarrays to examine transcripts from uninfected versus
KSHV-infected TIME cells during a 4-day time course of
infection and also UV-irradiated virus versus KSHV-
infected TIME cells to control for contaminants in the
inoculum that might effect host cell gene expression.
Analysis was done on glass slides spotted with approx-
imately 15000 or 13000 features in duplicate. As above,
at the time of harvest, subsets of cells were seeded onto
slides and stained with antibodies to LANA and ORF59.
The cells infected with UV-irradiated virus did not
express LANA or ORF59, while in the wild-type-infected
cells, greater than 90% of the cells stained for LANA
and less than 5% of the cells expressed ORF59. A total
of eight true biological replicates were done in duplicate
at three different time points, 24, 48, and 96 h after
infection with another set of duplicates performed at 48 h
with UV-irradiated virus-treated TIME cells as the
control. The effects of changes in gene expression in
cells undergoing lytic replication are minimal because
changes in expression in less than 5% of the cells will
not significantly impact the overall gene expression
patterns. In addition, it was recently demonstrated that
there is host gene shut off in lytically infected cells
(Glaunsinger and Ganem, 2004).
To analyze genes altered by KSHV infection, we chose
to only examine genes that were altered in all eight
experiments, indicating that the alterations were sustained
over the course of 4 days and, because we used UV-
irradiated virus in two experiments, alterations also
required viral gene expression. Cellular genes (147), about
1% of the total genes on the array, are altered at all time
points more than 1.8-fold in intensity with a P value of less
than 0.001. Expression of 86 genes is significantlyincreased at all time points (Table 1) while 61 genes are
significantly repressed by infection with KSHV (Table 2).
More than 10% of the genes that were identified as altered
by KSHV infection are similarly differentially expressed in
BECs versus LECs or in BECs differentiated into LECs by
forced expression of Prox-1 (Hirakawa et al., 2003; Hong
et al., 2002; Petrova et al., 2002). These changes are
indicated in bold in Tables 1 and 2. We have confirmed
many of these results by real-time RT-PCR looking at
transcripts altered by KSHV infection as well as some that
were unchanged on the arrays. Over 30 transcripts have
been analyzed by real-time RT-PCR and to date all the
genes tested are consistent with the results from the
microarrays (see Figs. 1A, 2, 3A and data not shown).
Expression of podoplanin is significantly increased on the
array (listed as T1A-2), confirming results from Fig. 1.
VEGFR3 is not spotted on the array.
Angiogenic genes
KSHV infection alters the expression of several genes
involved in angiogenesis. Included in the significantly altered
genes is FLT1 (VEGFR1), which is increased about 2-fold on
average (Table 1). Interestingly, FLT1 was previously shown
to be decreased in LECs versus BECs (Hirakawa et al., 2003),
indicating that KSHV is also altering gene regulation
unrelated to lymphatic differentiation. A set of experiments
was done to further quantify the alteration in expression of
genes involved in angiogenesis and to probe transcripts that
were not present on the array. Quantitative real-time RT-PCR
was done using commercially available TaqMan probes for
each transcript. As before, replicates (N = 3–5) were done on
different days with different viral stocks. As the microarray
experiments had shown, expression of VEGFR1 (FLT1) in
TIME cells is significantly increased, approximately 5-fold,
following KSHV infection, while VEGFR2 (KDR) is
relatively unchanged (Fig. 3). None of the VEGF family
members were greatly increased in expression. In fact, most
(VEGF-A, VEGF-B, and placental growth factor (PGF))
appeared to be slightly decreased, while VEGF-C was
slightly and consistently increased (Fig. 3). Interestingly,
Table 1
Genes upregulated by KSHV infection of TIME cells
Sequence name Sequence description Accession no. Fold change
SOCS3 suppressor of cytokine signaling 3 T72915 18.01
FLJ13220 hypothetical protein FLJ13220 AA083577 7.37
CEACAM1 carcinoembryonic antigen-related cell
adhesion molecule 1
(biliary glycoprotein)
AA406571 6.02
IL6 interleukin 6 (interferon, beta 2) W31016 5.82
LIPG lipase, endothelial T49529 5.22
GBP5 guanylate binding protein 5 AA487252 4.49
SLC21A2 solute carrier family 21
(prostaglandin transporter), member 2
AA037014 4.33
CALCRL calcitonin receptor-like N45301 3.96
T1A-2 lung type-I cell membrane-associated
glycoprotein (podoplanin)
AA046430 3.79
PMP22 peripheral myelin protein 22 R26732 3.47
DEPP decidual protein induced by
progesterone
N55269 3.34
SLC2A14 solute carrier family 2
(facilitated glucose transporter),
member 14
T97782 3.27
TMEM2 transmembrane protein 2 H75703 3.15
T1A-2 lung type-I cell membrane-associated
glycoprotein (podoplanin)
AA149827 3.06
SSB Sjogren syndrome antigen B
(autoantigen La)
H29484 2.96
STOM stomatin R62817 2.85
FHIT Homo sapiens cDNA FLJ46040 fis,
clone SPLEN2036475
AA256123 2.79
CA2 carbonic anhydrase II H23187 2.76
DEPP decidual protein induced by
progesterone
R33362 2.74
LTBP4 latent transforming growth factor beta
binding protein 4
R87406 2.69
PRSS2 protease, serine, 2 (trypsin 2) AA284528 2.68
EST_293336 2.58
ADAMTS1 a disintegrin-like and metalloprotease
(reprolysin type) with
thrombospondin type 1 motif, 1
R76276 2.56
DAF decay accelerating factor for complement
(CD55, Cromer blood group system)
R09561 2.56
ROM1 retinal outer segment membrane
protein 1
H84113 2.45
FLJ11795 hypothetical protein FLJ11795 AA459693 2.43
HIF1A hypoxia-inducible factor 1, alpha
subunit
(basic helix-loop-helix transcription
factor)
AA598526 2.38
IFIT2 interferon-induced protein with
tetratricopeptide repeats 2
N63988 2.35
ATF3 activating transcription factor 3 H21041 2.33
KIAA1450 KIAA1450 protein W31540 2.31
PBEF pre-B-cell colony-enhancing factor 2.3
KIAA0963 KIAA0963 protein AA476273 2.26
CD47 CD47 antigen (Rh-related antigen,
integrin-associated signal transducer)
R92801 2.25
PALM2 paralemmin 2 AA488418 2.23
IL6ST interleukin 6 signal transducer (gp130,
oncostatin M receptor)
T60500 2.2
SOD2 superoxide dismutase 2, mitochondrial AA487750 2.2
FLT1 fms-related tyrosine kinase 1 (vascular
endothelial growth factor/
vascular permeability factor receptor)
AA149508 2.18
ARRB1 Homo sapiens mRNA; cDNA DKFZp762M127
(from clone DKFZp762M127)
H20911 2.17
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Sequence name Sequence description Accession no. Fold change
GARP glycoprotein A repetitions predominant AA122287 2.13
E2-EPF ubiquitin carrier protein AA464019 2.12
NRCAM neuronal cell adhesion molecule R25521 2.11
LGALS9 lectin, galactoside-binding, soluble,
9 (galectin 9)
AA434102 2.08
C6orf4 chromosome 6 open reading frame 4 R78558 2.08
FLJ31265 hypothetical protein FLJ31265 H80258 2.07
SERPINB1 serine (or cysteine) proteinase inhibitor,
clade B (ovalbumin), member 1
R54664 2.07
UBE2L6 ubiquitin-conjugating enzyme E2L 6 AA292074 2.06
CTSL cathepsin L W73874 2.06
RPL7A ribosomal protein L7a H23421 2.04
NP nucleoside phosphorylase AA430382 2.03
KIAA0960 KIAA0960 protein N92895 2.02
KIAA1554 KIAA1554 protein H17860 2.02
KIAA1450 KIAA1450 protein N52875 2
IL1RL1 interleukin 1 receptor-like 1 AA128153 2
EST_139250 1.99
P2RY5 purinergic receptor P2Y, G-protein
coupled, 5
N90783 1.98
PROS1 protein S (alpha) T74191 1.97
PPAP2B phosphatidic acid phosphatase type 2B T72119 1.96
FLJ22269 hypothetical protein FLJ22269 AA463986 1.95
MMRN multimerin AA423867 1.95
SLC38A2 solute carrier family 38, member 2 R27255 1.94
ARHJ ras homolog gene family, member J W92399 1.93
LAPTM4B lysosomal associated protein
transmembrane 4 beta
AA600214 1.93
PRO1073 PRO1073 protein AA065090 1.92
NPC1 Niemann-Pick disease, type C1 AA634267 1.92
SP110 SP110 nuclear body protein R54613 1.91
EST_357298 Homo sapiens mRNA; cDNA
DKFZp762M127 (from clone
DKFZp762M127)
W93688 1.89
CD53 CD53 antigen AA132090 1.88
MGP matrix Gla protein AA155913 1.87
MTSG1 mitochondrial tumor suppressor gene 1 AA621202 1.87
M160 scavenger receptor cysteine-rich type 1
protein M160
N69291 1.87
MG61 Homo sapiens cDNA clone
IMAGE:5092935, partial cds
AA486843 1.85
EPAS1 endothelial PAS domain protein 1 AA680300 1.85
RALA v-ral simian leukemia viral oncogene
homolog A (ras related)
H97948 1.85
WARS tryptophanyl-tRNA synthetase AA664040 1.84
NNMT nicotinamide N-methyltransferase T72089 1.84
ETS2 v-ets erythroblastosis virus E26
oncogene homolog 2 (avian)
T46844 1.84
HS3ST1 heparan sulfate (glucosamine)
3-O-sulfotransferase 1
T55714 1.84
KIAA0564 KIAA0564 protein R24860 1.84
PTGS2 prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and
cyclooxygenase)
AA644211 1.84
KIAA0963 KIAA0963 protein AA485433 1.84
FLJ25084 hypothetical protein FLJ25084 R62633 1.83
GDAP1 ganglioside-induced
differentiation-associated protein 1
H15302 1.83
RANBP1 RAN binding protein 1 1.83
SPRY4 Homo sapiens cDNA FLJ26120 fis,
clone SYN00419
R70506 1.82
CXCL16 chemokine (C-X-C motif) ligand 16 AA416552 1.82
POPDC3 popeye domain containing 3 N20482 1.82
Bold denotes similar regulation in lymphatic endothelial cells.
Table 1 (continued )
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Table 2
Genes downregulated by KSHV infection of TIME cells
Sequence name Sequence description Accession no. Fold change
EST_261253 Homo sapiens cDNA FLJ43100 fis,
clone CTONG2003100
H98248 1.82
EST_23588 Homo sapiens, Similar to hypothetical
protein LOC216438, clone
IMAGE:4444559, mRNA, partial cds
R38369 1.83
EST_322537 Homo sapiens MSTP157 (MST157)
mRNA, complete cds
W15263 1.83
TPM1 tropomyosin 1 (alpha) W58009 1.83
VASP Homo sapiens transcribed
sequence with strong similarity to
protein pir:S51797 (H. sapiens)
S51797 vasodilator-stimulated
phosphoprotein—human
AA410429 1.84
CDC6 CDC6 cell division cycle 6 homolog
(S. cerevisiae)
H59203 1.85
BIRC5 baculoviral IAP repeat-containing 5
(survivin)
AA460685 1.86
ITGA10 integrin, alpha 10 H43656 1.87
MN1 meningioma
(disrupted in balanced translocation) 1
R59212 1.87
FOSL1 Homo sapiens mRNA;
cDNA DKFZp666J045
(from clone DKFZp666J045)
T82817 1.88
CTCF CCCTC-binding factor
(zinc finger protein)
H89996 1.88
UBE2C ubiquitin-conjugating enzyme E2C AA430504 1.89
AKR1C1 aldo-keto reductase family 1, member C1
(dihydrodiol dehydrogenase 1; 20-alpha
(3-alpha)-hydroxysteroid dehydrogenase)
R93124 1.89
MYBL2 v-myb myeloblastosis viral oncogene
homolog (avian)-like 2
AA456878 1.9
DOC1 downregulated in ovarian cancer 1 W69790 1.9
EST_782847 Homo sapiens transcribed sequences AA448283 1.9
EST_415584 Homo sapiens transcribed sequence
with moderate similarity to protein
ref:NP_060265.1
(H. sapiens) hypothetical
protein FLJ20378 [Homo sapiens]
W78816 1.91
CARP cardiac ankyrin repeat protein AA486364 1.92
EST_501430 Homo sapiens cDNA FLJ31353 fis,
clone MESAN2000264.
AA115248 1.92
PVRL3 poliovirus receptor-related 3 R62780 1.92
SEC15L1 SEC15-like 1 (S. cerevisiae) AA187002 1.93
UAP1 UDP-N-acteylglucosamine
pyrophosphorylase 1
N68465 1.93
CXCL1 chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating
activity, alpha)
W42723 1.95
COL1A2 collagen, type I, alpha 2 W93067 1.96
IL8 interleukin 8 AA102526 1.97
PTTG1 pituitary tumor-transforming 1 AA430032 1.97
ALCAM activated leukocyte cell adhesion
molecule
R39862 1.98
EGR3 early growth response 3 R39111 1.98
FJX1 four jointed box 1 (Drosophila) H72460 2
HMGA1 high mobility group AT-hook 1 AA448261 2.02
KRT7 keratin 7 AA489569 2.03
HRB2 HIV-1 rev binding protein 2 W52272 2.05
EST_201562 Homo sapiens transcribed sequences R97050 2.05
EST_171753 Homo sapiens surfactant associated
protein F mRNA,
partial sequence, mRNA sequence
H18335 2.06
RGS4 regulator of G-protein signaling 4 AA007419 2.07
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EPLIN epithelial protein lost in neoplasm beta AA491501 2.09
MICAL2 flavoprotein oxidoreductase MICAL2 AA412582 2.1
EST_130826 Homo sapiens transcribed sequences R22189 2.11
FN14 IMAGE EST: 135791;Unigene:
Hs.10086; type I transmembrane
protein Fn14
2.12
CDCA1 cell division cycle associated 1 AA421171 2.19
EST_140301 Homo sapiens cDNA FLJ11041 fis,
clone PLACE1004405.
R66924 2.19
ESDN endothelial and smooth muscle
cell-derived neuropilin-like protein
AA431438 2.24
IRS1 insulin receptor substrate 1 AA460841 2.27
PDCD1L1 programmed cell death 1 ligand 1 R78465 2.29
RRM2 ribonucleotide reductase M2 polypeptide AA187351 2.29
EST_140966 Homo sapiens LOC158525
(LOC158525), mRNA
R66502 2.31
HRB2 HIV-1 rev binding protein 2 AA251800 2.32
TRB@ Homo sapiens TCR BV3 mRNA for
T cell receptor beta chain (CDR3 region),
partial cds, isolate:HTLV-1 myopathy
case3, clone:Tax tetramer-5.
N91921 2.34
DJ667H12.2 hypothetical protein DJ667H12.2 AA608531 2.37
CCNA2 cyclin A2 AA608568 2.37
ESDN endothelial and smooth
muscle cell-derived RG_TX_tbl2neuropilin-like
protein
N21309 2.39
ESDN endothelial and smooth muscle
cell-derived neuropilin-like protein
H99543 2.44
COL1A2 collagen, type I, alpha 2 AA490172 2.56
EST_80186 Homo sapiens T cell receptor beta chain
BV20S1 BJ1-5 BC1 mRNA, complete cds
T64380 2.84
SEMA3C sema domain, immunoglobulin domain (Ig),
short basic domain, secreted, (semaphorin) 3C
AA042990 3.12
LRRC17 leucine rich repeat containing 17 AA423870 3.19
XRCC1 X-ray repair complementing defective AA425139 3.25
CDKN2B repair in Chinese hamster cells 1 cyclin-dependent
kinase inhibitor 2B (p15, inhibits CDK4)
N34320 3.45
Bold denotes similar regulation in lymphatic endothelial cells.
Table 2 (continued )
Rapid Communication 13expression of VEGF-B and PGF is decreased in LECs
versus BECs (Hirakawa et al., 2003; Petrova et al., 2002),
again consistent with KSHV-induced differentiation. Cul-
tured LECs, but not BECs, respond to VEGF-C, both as a
mitogen and chemoattractant (Makinen et al., 2001), and
VEGF-C is present in KS lesions (Skobe et al., 1999).
VEGF-C was previously shown to be decreased signifi-
cantly in LECs versus BECs. However, it was not
repressed by forced Prox-1 expression in BECs (Petrova
et al., 2002), only in mixed culture primary DMVECs
(Hong et al., 2002). Thus, KSHV infection of BECs
appears to drive the differentiation to LECs, while the
increase in VEGFR3 expression and the concomitant
induction of VEGF-C raise the possibility of an autocrine
loop for cell activation.
We also found that carcinoembryonic antigen-related
cell adhesion molecule 1 (CEACAM1) was increased about
18-fold (Fig. 3), which was consistently one of the most
induced genes upon BEC to LEC differentiation (Hirakawa
et al., 2003; Petrova et al., 2002).Cytokines and KSHV infection
Because many cytokines are expressed in KS tumors and
cytokine dysregulation has been proposed to play an
important role in KS genesis, the alteration of cytokines
was further analyzed. One of the most highly induced genes is
hIL-6. hIL-6 is a cytokine involved in B-cell activation but
may also play many other roles including a role in tumor
formation. Importantly, hIL-6 is present at high levels in the
KS tumor (Oxholm et al., 1989). The expression of hIL-6
after infection was further analyzed by real-time RT-PCR,
where its transcript was increased approximately 44-fold on
average after infection (Fig. 4A). Inhibition of cytokines may
play a role in KS formation by immune evasion or more
directly through changes in the activation of different cell
types. Expression of IL-8, a chemokine that is capable of
attracting neutrophils and T-cells (Hoffmann et al., 2002), is
significantly inhibited at all three time points after KSHV
infection. As described above, the inhibition of IL-8 is also
consistent with the differentiation of TIME cells from blood
Fig. 3. KSHV infection of TIME cells alters transcripts involved in
angiogenesis. Depicted is the fold change of angiogenesis-related tran-
scripts in KSHV-infected TIME cells compared to UV-irradiated virus
treated cells at 48 h postinfection as determined by real-time RT-PCR (N =
3–5). All values were normalized to GAPDH expression and error bars
represent the standard error of the mean.
Rapid Communication14to lymphatic endothelium. The expression of IL-8 was further
analyzed by real-time RT-PCR, where a decrease of
approximately 8-fold was seen at 48 h postinfection with
KSHV (Fig. 4A).
To analyze the protein levels of IL-6, IL-8, and a large
number of other cytokines, a cytokine antibody array was
used to monitor secreted proteins, as described in Materials
and methods. Media from uninfected and infected cells were
used to probe a membrane spotted with antibodies to 79
different cytokines and the relative levels of cytokines were
determined. A representative experiment is shown from
uninfected and KSHV-infected primary DMVECs at both 48
and 96 h postinfection (Fig. 4B). Similar results were
obtained with TIME cells at 48 and 96 h postinfection (data
not shown). Matching the mRNA expression data, hIL-6
protein levels in the media was significantly increased while
IL-8 protein levels in the media were strongly decreased by
KSHV infection. The only other cytokine that was altered
was monocyte chemoattractant protein-1 (MCP-1), which
was decreased at both 48 and 96 h postinfection. MCP-1
expression is also decreased in LECs versus BECs
(Hirakawa et al., 2003; Petrova et al., 2002), again
consistent with KSHV-infection reprogramming BECs to
behave like LECs. These data also demonstrate that the
cytokine changes are not unique to TIME cells but are also
seen after infection of primary endothelial cells.Fig. 4. KSHV infection of endothelial cells alters cytokine production and
secretion. (A) Depicted is the fold change of IL6 and IL8 transcripts in
KSHV-infected TIME cells compared to UV-irradiated virus treated cells at
48 h postinfection as determined by real-time RT-PCR (N = 3). All values
were normalized to GAPDH expression and error bars represent the
standard error of the mean. (B) A cytokine antibody array was used to
monitor secreted cytokines from KSHV-infected and mock-infected
primary human DMVECs by probing the antibody-spotted membrane with
diluted supernatants from 48 to 96 h postinfection.Discussion
In vivo, KS spindle cells express markers of the lymphatic
endothelium and it was proposed that KS was lymphatic
endothelium in origin (Weninger et al., 1999). The data
presented here indicate that, rather than infecting lymphatic
endothelial cells, KSHV could infect blood or circulatingendothelial precursor cells and drive them to differentiate into
lymphatic endothelial cells as they become spindle cells.
Developmental work has shown that the lymphatic vascula-
ture buds from the existing blood vasculature as a result of the
initiation of a distinct differentiation pathway in the
endothelial cells (Oliver and Harvey, 2002). Expression of
Prox-1 is specific to lymphatic endothelial cells and mice that
were deficient in Prox-1 had a normal blood vasculature but
had no lymphatic system. While we could detect Prox-1 in
primary microvascular endothelial cells (Carroll and Lagun-
off, data not shown), which are known to contain significant
percentages of LECs, we could not detect expression in TIME
cells, indicating that TIME cells do not contain LECs and are
BEC derived. Furthermore, only after infection with KSHV
could we detect Prox-1 mRNA in TIME cells (Fig. 1B). We
obtained quantitative data for three other major markers of
lymphatic endothelium, VEGFR3, podoplanin, and LYVE-1
Rapid Communication 15(Fig. 1A), and data demonstrating an increase in protein
levels for two of the markers, VEGFR3 and podoplanin (Fig.
1C). Global analysis of TIME cell changes after infection
yielded many more changes consistent with differentiation
into the lymphatic endothelium. Ten percent of the most
significant alterations after KSHV latent infection was
differentially expressed between BECs and LECs and many
of these changes were also altered when Prox-1 was used to
drive differentiation of BECs to LECs (bold in Tables 1 and
2). Taken together, these data demonstrate that KSHV
recapitulates many of the aspects of differentiation from
BEC to LEC via Prox-1, but the fact that some of the changes
are similar to other array data comparing BECs to LECs
(Hirakawa et al., 2003; Petrova et al., 2002), but not with
forced expression of Prox-1 alone in BECs (Hong et al., 2002;
Petrova et al., 2002), suggests that KSHV may induce
differentiation effects distinct from Prox-1 in addition to the
changes programmed by Prox-1.
There is a large amount of neo-angiogenesis in KS tumors.
Whether KSHV infection directly induces angiogenesis or if
the effects are indirect is unknown. If KSHV directly induces
angiogenesis, this study indicates that factors involved in
lymphangiogenesis not hemangiogenesis should be ana-
lyzed. Lymphangiogenesis does not revolve around VEGF-
A, but rather VEGF-C or VEGF-D is the main growth factor.
The receptor for VEGF-C or D is VEGFR3, which is highly
upregulated in infected cells. Interestingly, VEGF-C was
shown to induce growth of KS spindle cells in culture
(Marchio et al., 1999). While these cells are abnormal in
chromosome number and no longer maintain KSHV, they
were most likely infected with KSHV in vivo and sub-
sequently lost the virus upon growth in culture. Thus, it is
possible that the differentiation to lymphatic endothelium is
irreversible in these cells and they now respond to VEGF-C
because they are lymphatic endothelial cells. There are other
changes in genes involved in angiogenesis that are not
completely consistent with lymphatic differentiation. The
twomost prominent are VEGFR1, which is increased slightly
on the array and by real-time RT-PCR, and the slight increase
in VEGF-C. An increase in VEGF-C is very interesting
because that could induce an autocrine loop in infected cells.
Further work is underway to determine the role of VEGF-C in
infected cells. VEGFR1 has been described as both a negative
and a positive regulator of hemangiogenesis. If it is acting
positively, it would be interesting to have an infected cell that
can respond gratuitously to both lymphangiogenic and
hemeangiogenic stimuli simultaneously.
Changes in the cytokine milieu have been proposed to
play a major role in KS pathogenesis. The studies presented
here identified three cytokines that are altered following
KSHV infection. hIL-6 is one of the most highly upregu-
lated genes following KSHV infection while IL-8 is one of
the most significantly downregulated genes. MCP-1 secre-
tion is also decreased upon infection with KSHV. IL-8 and
MCP-1 decreases are consistent with differentiation from
blood to lymphatic endothelial cells. In KS tumors, hIL-6 isfound in high levels. As with VEGFR3 and podoplanin,
changes in infected TIME cells in culture mimic gene
expression seen in KS tumors in vivo. The role of hIL-6 in
KS tumors is unknown but may be part of the interplay of
infiltrating lymphocytes and spindle cells.
Three other studies have analyzed host gene expression
following KSHV infection of endothelial cells. Two studies
used commercially available primary DMVECs (Naranatt et
al., 2004; Poole et al., 2002). The third study used a
DMVEC line that was immortalized with E6 and E7 from
human papilloma virus (Moses et al., 2002), two potent
oncogenes. None of these studies noted the large number of
lymphatic endothelial cell changes that we found here. Both
studies done at later times postinfection contained a few
changes consistent with lymphatic differentiation, but
neither noted the major markers of lymphatic endothelium.
It is possible that the arrays used did not have many of the
lymphatic-specific genes. For example, the cDNA array we
used did not contain VEGFR3, the changes were deter-
mined solely by real-time RT-PCR and at the protein level.
However, it is important to note again that commercially
available primary cells contain a significant percentage of
lymphatic endothelial cells and thus many of the changes
due to differentiation could be dampened. We have analyzed
many of the genes described in primary DMVECs as well,
and all of the genes are altered in a similar, yet in some
cases diminished, fashion (Carroll and Lagunoff, unpub-
lished). The most recent study examined cells at 2 and 4 h
(Naranatt et al., 2004), before latency has been established
and there is much more complex viral gene expression not
directly relevant to latent gene expression (Krishnan et al.,
2004). In the E6/E7 immortalized DMVECs, the authors
found that VEGFR2 is upregulated (Moses et al., 2002).
This hallmark of blood endothelial cells is not seen after
latent infection of primary cells in the other study or our
experiments (Poole et al., 2002). Of note, E7 can destabilize
chromosomes leading to aneuploidy (Duensing and
Munger, 2002), and E6 targets p53 for degradation
(Scheffner et al., 1990), which can have multiple effects
on angiogenesis and tumorigenesis (Ravi et al., 2000).
Overall, this study demonstrates the potential for KSHV
to alter the differentiation state of endothelial cells. Because
KS spindle cells express markers of LECs and KSHV
infection of BECs in culture leads to upregulation of
lymphatic markers, we believe that KSHV may infect blood
endothelial cells or other endothelial cell types in vivo and
drive their differentiation to lymphatic endothelial cells.
However, the question remains, what is the role of lymphatic
differentiation in KSHV biology? It is possible that differ-
entiation induces the cells to a state where latency is better
established or where the infected cells are better suited to
expand and spread though the body via the lymphatic
system and VEGFR3-mediated mitogenic stimulation. Fur-
ther studies are ongoing to determine the functional effects
of the alterations of these genes on endothelial cells and how
they might be advantageous for KSHV.
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Cells
BCBL-1 cells are a KSHV-positive, EBV-negative B-cell
line derived from a primary effusion lymphoma maintained
as described elsewhere (Renne et al., 1996). TIME cells are
a tert-immortalized dermal microvascular endothelial cell
line (DMVEC) maintained as described elsewhere (Lagun-
off et al., 2002). Primary human DMVECs (Clonetics) were
cultured under the same conditions as the TIME cells.
Virus isolation and infections
Virus was isolated as before (Lagunoff et al., 2002) and
was titered on TIME cells to determine the optimal amount
of virus to achieve greater than 90% latent infection and
less than 5% lytic infection, as determined by immuno-
fluorescence assay (Lagunoff et al., 2002) using anti-
LANA (a kind gift from A. Polson and D. Ganem) and
anti-ORF59 (a kind gift from B. Forghani or purchased
from ABI). Alexafluor 488 or 594 nm labeled secondary
antibodies were used (Molecular Probes, Oregon). Slides
were mounted in DAPI containing mounting media,
Vectashield (Vector Laboratories, Inc.), then scored on a
fluorescent microscope. Immunofluorescence staining with
anti-podplanin antibody, purchased from AngioBio Co.
(Del Mar, CA), was done similarly as above except
methanol was used to fix the cells and fetal bovine serum
was used as a block. The pictures in Fig. 2 were taken for
each fluor under identical conditions between mock- and
KSHV-infected cells.
RNA isolation and cDNA generation
Total RNA was isolated from TIME cells using RNAbee
as recommended by the manufacturer (Tel-Test, Texas).
Enrichment of polyadenylated mRNA was done using the
Oligotex Kit as recommended by the manufacturer (Qiagen).
For the first set of experiments, 8 Ag of polyA-enriched RNA
was labeled for microarray as described elsewhere (Geiss et
al., 2001). For the second round of experiments, mRNAwas
amplified using the RiboAmp RNA Amplification Kit, as
recommended by the manufacturer (Arcturus). Labeled
cDNA was then made as described above. cDNA for real-
time RT-PCR was generated from 100 ng of isolated mRNA
using the SuperScript First-Strand Synthesis System accord-
ing to the manufacturers directions (Invitrogen).
Microarray analysis
Slides for analysis were spotted at the University of
Washington’s Center for Expression Array as described
elsewhere (Geiss et al., 2001). Labeled cDNAs from the first
set of experiments were hybridized to approximately 15000
gene array spotted in duplicate on two slides. Eachexperiment was done with the control and experimental
cDNA labeled with cy3 and cy5 and then repeated with the
labels reversed. The second round of experiments was done
on approximately 13000 gene array identical to the original
array except for the absence of approximately 2000 spots.
RNA for each time point was isolated from different
infections, performed on different days, using different viral
stocks. Microarray data were analyzed using the University
of Washington’s Center for Expression Array and the
Resolver Biosoftware Package (Rosetta Inpharmatics).
Real-time and semi-quantitative RT-PCR
cDNA was generated as stated above, and commercially
available TaqMan probes (Assays-on-Demand) were used,
following the manufacturers directions (Applied Biosys-
tems). iTaq DNA Polymerase (Biorad) was used for the
amplification of 2 Al of cDNA with the TaqMan probes,
and the reactions were monitored on an Icycler thermo-
cycler (Biorad). Changes in relative abundance of transcript
were normalized to GAPDH expression (Threshold cycle,
CT) compared to control expression in UV-irradiated
KSHV-treated TIME cells using the following equation
(CT of experimental gene in control cells minus CT of
GAPDH) minus (CT of experimental gene in KSHV-
infected cells minus CT of GAPDH). For semi-quantitative
RT-PCR, 5–160 ng of mRNAwas amplified using the One-
Step RT-PCR kit (Qiagen) as recommended using the
following 5V to 3V primers; Prox-1 F: CCCGGATCCGT-
GATGCCTGACCATGAC, Prox-1 R: AAACCCGTC-
GACTTTCTACTCATGAAGCAGCTC and GAPDH F:
AAGGTGAAGGTCGGAGTCAACG, GAPDH R:
TGGAAGATGGTGATGGGATTTC. The Prox-1 primers
are tailed with restriction sites. The product resulting from
RT-PCR with these primers was sequenced and found to
perfectly match the human Prox-1 sequence.
Western blot analysis
Forty-eight hours postinfection, KSHV-infected and
mock-infected TIME cells were lysed in RIPA lysis buffer
(50 mM Tris–HCL, pH 7.6, 150 mM NaCl, 1 mM EDTA,
1% Triton X-100, 1% sodium deoxycholate, and 0.1%
sodium dodecyl sulfate supplemented with 0.5 mM dithio-
threitol, 0.4 mM phenylmethylsulfonyl fluoride, 2 Ag/ml
each of aprotinin, pepstatin, and leupeptin, and 1 mM
sodium ortho-vanadate). Protein in the lysis supernatant was
quantified by BCA assay (Pierce), and 20 or 40 Ag of total
protein was subjected to SDS-PAGE. After transfer to
PVDF (Immobilon-P, Millipore), the blot was probed with
the following primary antibodies: rabbit anti-podoplanin
(Research Diagnostic Inc, RDI-102PA40), rabbit anti-
VEGFR3 (Santa Cruz, SC-321), and mouse anti-COX1
(Cayman Chemical, 160110), then washed and probed with
either goat anti-mouse or goat anti-rabbit (Jackson Immu-
noResearch Laboratories). Chemiluminescence was then
Rapid Communication 17performed using ECL+ Plus (Amersham) and exposing to
Blue X-Ray Film (Phenix Research Products).
Cytokine antibody array
DMVECs were infected with KSHVor mock infected for
42 and 90 h. Media were replaced with serum-free media and
left on the cells at 37 8C for 6 h. The serum-free media were
then harvested, cellular debris was centrifuged out, and the
supernatant was diluted 1:5 and used as the probe on aHuman
Cytokine Array V spotted with antibodies to 79 different
cytokines (RayBiotech, Inc.). The membrane was treated as
recommended by the manufacturer. After the final wash the
membrane was developed using ECL+ Plus Western Blotting
Detection System (Amersham Biosciences).Note added in proof
Two manuscripts demonstrating similar KSHV induced
lymphatic differentiation were published while this manu-
script was in press, Y.-K. Hong et al. Nature Genetics, 2004,
36: 683–85 and H.-W. Wang et al. Nature Genetics, 2004,
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